Genetic polymorphisms in diabetics and non-diabetics

D. R. R. WILLIAMS AND R. A. CARTWRIGHT

From the MRC Dunn Clinical Nutrition Centre, Addenbrookes Hospital, Trumpington Street, Cambridge CB2 1QE; and the Yorkshire Regional Cancer Organisation, Cookridge Hospital, Leeds LS16 6QB

SUMMARY Phenotype distributions of some genetic polymorphisms are reported in a sample of 721 diabetics and 515 non-diabetic, non-blood donor controls. Reference is also made, in the case of the ABO and Rhesus systems, to previously published results for blood donors resident in the Durham area. Non-insulin-taking diabetics show an increased frequency of blood group A₁ (and A₁ + A₂) when compared with controls. This difference is particularly marked in male diabetics. When diabetics are compared with age matched controls, the difference is confined to the older cases. It is proposed that this effect is predominantly the result of a deficiency of group A₁ in controls rather than the result of increased susceptibility to the disease among A₁ people. No association with any of the Rhesus phenotypes is shown. In non-diabetics, the results suggest an enhanced survival value for the rr genotype.

No significant associations are seen when the MNSs, Kell, Lewis, Duffy, haptoglobin, red cell acid phosphatase, phosphoglucomutase, adenylate kinase, and adenosine deaminase distributions in these groups of subjects are compared.

The ABO blood groups of diabetics have been extensively studied since McConnell's suggestion, in 1955, of an increased frequency of blood group A in these patients. Despite considerable effort, however, this approach has contributed little to knowledge of the hereditary factors involved in the predisposition to diabetes, and there has been some measure of disagreement among the authors concerned. Other red cell polymorphisms and serum protein systems have been less well studied in diabetics and few clear conclusions have been drawn.

The present study was undertaken to investigate the distribution of some of these polymorphisms in diabetics and in non-diabetic controls. The results for the esterase-D polymorphism in these subjects have been published elsewhere (Williams and Cartwright, 1978), as have those for the histocompatibility antigens (Williams, 1977).

Two features distinguish this particular study. Firstly, the sample of diabetics consists of a large proportion of the out-patients attending one particular hospital, and the phenotype frequencies in these patients are analysed in terms of current treatment, current age, and sex. Secondly, the controls are drawn from the same geographical area as the diabetics, are age matched with them for analysis, and are not a sample of blood donors, though previously published data from donors are included for comparison.

Materials and methods

DIABETIC SUBJECTS

Patients were chosen from those attending out-patient clinics at Dryburn Hospital, Durham. Venous blood samples were taken from 721 of the diabetics attending between November 1974 and June 1976. This represents about 75% of the total attendance during this time. Sampling was not random since patients attending more frequently had a greater chance of selection. The series collected was slightly younger in mean age and consisted of a higher proportion of insulin-taking patients and a lower proportion of diet-treated patients than the complete out-patient population, though these differences were not significant (Williams, 1977).

CONTROL SUBJECTS

These were selected from three sources: (a) age and sex matched neighbours of some of the diabetics (72 subjects); (b) patients attending the orthopaedic department of Dryburn hospital for treatment of traumatic conditions, mainly fractures and head
injuries (397 subjects); and (c) students at the University of Durham whose permanent address was within County Durham (46 subjects). These subjects were accepted as controls only after proving the absence of glycosuria. Urine samples were taken 1 to 2 hours after the largest meal of the day in the neighbour group, during routine ward testing in the orthopaedic group, and at entry to the University in the student group.

The ABO and Rhesus (D) results were compared with previously published frequencies for blood donors resident in the area by summation of the results given by Kopeć (1970) for the following areas: Stanley, Birtley, Washington, Chester-le-Street, Houghton-le-Spring, Seaham, Easington, Horden, Durham, Spennymoor, Ferryhill, and Crook.

**Blood Grouping and Electrophoresis**

Venous blood was taken into heparinised tubes and, after centrifugation and removal of serum, the erythrocytes were washed three times in saline and resuspended in a 4% solution.

All samples were tested with anti-A, anti-B, anti-AB, anti-C, anti-c, anti-D, and anti-E antisera. Those positive with anti-E were also tested with anti-e. Varying numbers of the samples (depending on the availability of antisera) were tested with anti-M, anti-N, anti-S, anti-s, anti-Le (a), anti-FyA, and anti-Fyb. First-line antisera were gifts from various sources (see acknowledgements). Confirmation of uncommon Rhesus phenotypes was carried out with second-line antisera derived from commercial sources (Ortho and Biotest). Most samples were grouped in parallel with commercial control cells, all grouping being completed within 24 hours of the blood being taken.

Haptoglobin, red cell acid phosphatase, phosphorylase, adenylate kinase, and adenosine deaminase characterisations were performed by starch gel electrophoresis using a number of methods summarised elsewhere (Williams, 1977).

**Analysis**

Statistical analysis was performed on an IBM 370/167 computer complex using facilities available in the Statistical Package for Social Sciences (SPSS).

**Results**

**Place of Birth**

A total of 92% of the controls and 60% of the diabetics were asked for their county of birth. There were no significant differences between the two groups (Table 1). Parental place of birth was also asked of these subjects and there were, similarly, no differences between the diabetics and controls with regard to the proportion with two, one, or none of parents born in County Durham.

**Disease Status**

The ABO results for diabetics and non-diabetics, without regard to age or sex are shown in Table 2. Diabetics are subdivided into insulin-taking and non-insulin-taking, since there were no significant differences in the ABO phenotype frequencies between the 252 oral hypoglycaemic-treated and the 239 diet-treated patients.

The frequencies of the subtypes of group A and AB are not available for blood donors. For the purpose of comparison, the numbers of diabetics and controls without subdivision of groups A and AB are given. The differences between the donors and the non-donor controls are small and not statistically significant. There are no significant differences between the phenotype frequencies of the insulin-taking diabetics and of either of the two control groups.

**Table 1 County of birth of diabetics and non-blood donor controls (counties previous to 1974 reorganisation)**

<table>
<thead>
<tr>
<th>Birth place</th>
<th>Diabetics</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>County Durham</td>
<td>326 (75.3%)</td>
<td>346 (72.7%)</td>
</tr>
<tr>
<td>Neighbouring counties (Northumberton, Westmorland, Cumber-land, and Yorkshire)</td>
<td>31 (7.2%)</td>
<td>34 (7.1%)</td>
</tr>
<tr>
<td>Elsewhere in UK</td>
<td>34 (7.8%)</td>
<td>40 (8.4%)</td>
</tr>
<tr>
<td>Unsure of birth place</td>
<td>42 (9.7%)</td>
<td>56 (11.8%)</td>
</tr>
<tr>
<td>Total asked</td>
<td>433</td>
<td>476</td>
</tr>
</tbody>
</table>

**Table 2 ABO phenotype frequencies in diabetics and controls**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Insulin-taking diabetics</th>
<th>Non-insulin-taking diabetics</th>
<th>All diabetics</th>
<th>Non-blood donor controls</th>
<th>Blood donor controls (Kopeć, 1970)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>76 (33.0%)</td>
<td>186 (37.9%)</td>
<td>262 (36.3%)</td>
<td>161 (31.3%)</td>
<td>1849 (38.3%)</td>
</tr>
<tr>
<td>A2</td>
<td>13 (5.7%)</td>
<td>34 (6.9%)</td>
<td>47 (6.5%)</td>
<td>36 (6.5%)</td>
<td>309 (6.1%)</td>
</tr>
<tr>
<td>A1 + A2</td>
<td>89 (38.7%)</td>
<td>220 (44.8%)</td>
<td>309 (42.8%)</td>
<td>197 (38.3%)</td>
<td>1849 (38.3%)</td>
</tr>
<tr>
<td>O</td>
<td>106 (46.1%)</td>
<td>215 (43.8%)</td>
<td>321 (44.5%)</td>
<td>255 (49.5%)</td>
<td>2367 (49.0%)</td>
</tr>
<tr>
<td>B</td>
<td>29 (12.6%)</td>
<td>44 (9.0%)</td>
<td>73 (10.1%)</td>
<td>47 (9.1%)</td>
<td>443 (9.2%)</td>
</tr>
<tr>
<td>A1B</td>
<td>4 (1.7%)</td>
<td>8 (1.6%)</td>
<td>12 (1.7%)</td>
<td>12 (2.3%)</td>
<td>19 (3.8%)</td>
</tr>
<tr>
<td>A2B</td>
<td>2 (0.9%)</td>
<td>4 (0.8%)</td>
<td>6 (1.2%)</td>
<td>4 (0.8%)</td>
<td>174 (3.3%)</td>
</tr>
<tr>
<td>A1B + A2B</td>
<td>6 (2.6%)</td>
<td>14 (2.4%)</td>
<td>20 (3.1%)</td>
<td>16 (3.1%)</td>
<td>4833 (9.3%)</td>
</tr>
</tbody>
</table>

Total 230 491 721 515 4833
groups, but the non-insulin-taking diabetics differ from both control groups and from the insulin-taking diabetics in having a higher frequency of group A₁ (and, therefore, of A₁ + A₂), and a lower frequency of group O. These differences are expressed in terms of A₁/O and A/O ratios in Table 3. χ² values are calculated by the method of Woolf (1955). The relative incidences differ significantly (P < 0.05) from unity when non-insulin-taking diabetics are compared with either control group. The diabetic group as a whole differs significantly only from the larger donor control group.

Rhesus phenotype frequencies in diabetics and controls are given in Table 4 (D only) and Table 5 (results with all antisera used). Results for the donors are only available for the D locus.

The frequency of Rhesus negative subjects in the blood donor group (Table 4) is higher than in the non-blood donor controls and the diabetic groups, but none of these differences is statistically significant in these samples.

The deficiency of the CcDee phenotype among insulin-taking diabetics (Table 5) is not significant (χ² = 9.49 for 5 degrees of freedom, the two smallest categories having been amalgamated, 0.1 > P > 0.05).

The remaining polymorphisms showed no significant differences between diabetics and non-diabetics.

### AGE AND SEX
There are no analyses of the ABO and Rhesus systems by age or sex for blood donors in the Durham area. When the ABO phenotype frequencies of diabetics and age matched controls (non-blood donors) are compared (Table 6), the largest differences are seen to lie in the oldest group. The A₁/O relative incidence in this group is 1.69 (χ² with one degree of freedom = 6.16, P < 0.025). It does not differ significantly from unity in the other two age groups. It may be seen that, in the diabetics, the frequency of group A₁ increases with increasing age.

---

### Table 3 Relative incidence (ABO system) in diabetics and controls

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Relative incidence (x) A₁/O</th>
<th>Relative incidence (x) A₁/O</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x</td>
<td>χ² (df = 1)</td>
</tr>
<tr>
<td>Insulin-taking diabetics vs non-blood donor controls</td>
<td>1.13</td>
<td>0.46</td>
</tr>
<tr>
<td>Non-insulin taking diabetics vs non-blood donor controls</td>
<td>1.37</td>
<td>4.92</td>
</tr>
<tr>
<td>All diabetics vs non-blood donor controls</td>
<td>1.29</td>
<td>3.80</td>
</tr>
<tr>
<td>Insulin-taking diabetics vs blood donor controls</td>
<td>1.07</td>
<td>0.21</td>
</tr>
<tr>
<td>Non-insulin taking diabetics vs blood donor controls</td>
<td>1.29</td>
<td>5.86</td>
</tr>
</tbody>
</table>

---

### Table 4 Rhesus (D) results for diabetics and controls

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Insulin-taking diabetics</th>
<th>Non-insulin-taking diabetics</th>
<th>All diabetics</th>
<th>Non-blood donor controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhesus (D) 39</td>
<td>87</td>
<td>126</td>
<td>89</td>
<td>927</td>
</tr>
<tr>
<td>Rhesus (D) 190</td>
<td>405</td>
<td>595</td>
<td>426</td>
<td>3906</td>
</tr>
<tr>
<td>Positive (83.0%)</td>
<td>(82.3%)</td>
<td>(82.5%)</td>
<td>(82.7%)</td>
<td>(80.8%)</td>
</tr>
<tr>
<td>Totals</td>
<td>229</td>
<td>492</td>
<td>721</td>
<td>515</td>
</tr>
</tbody>
</table>

---

### Table 5 Rhesus phenotypes in diabetics and controls

<table>
<thead>
<tr>
<th>Reaction with anti-C</th>
<th>c</th>
<th>D</th>
<th>E</th>
<th>e</th>
<th>Probable genotype</th>
<th>Insulin-taking diabetics</th>
<th>Non-insulin-taking diabetics</th>
<th>All diabetics</th>
<th>Non-blood donor controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>r r</td>
<td>37 (16.2%)</td>
<td>82 (16.7%)</td>
<td>119 (16.5%)</td>
</tr>
<tr>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>R₁r</td>
<td>65 (28.4%)</td>
<td>180 (36.6%)</td>
<td>245 (34.0%)</td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>R₁R₁</td>
<td>54 (23.6%)</td>
<td>85 (17.3%)</td>
<td>139 (19.3%)</td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>R₁r</td>
<td>20 (8.7%)</td>
<td>44 (8.9%)</td>
<td>64 (8.9%)</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>R₁R₁</td>
<td>6 (2.6%)</td>
<td>5 (1.0%)</td>
<td>11 (1.5%)</td>
</tr>
<tr>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>R₁r</td>
<td>29 (13.0%)</td>
<td>87 (17.7%)</td>
<td>126 (17.6%)</td>
</tr>
<tr>
<td>Others</td>
<td>R₁r, r r, r r</td>
<td>8 (3.5%)</td>
<td>9 (1.8%)</td>
<td>17 (2.4%)</td>
<td>14 (2.7%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Totals</td>
<td>229</td>
<td>492</td>
<td>721</td>
<td>515</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
at the expense of group O. In controls the reverse is the case, with a decline in the frequency of A2 and an increase in that of group O. None of these trends is statistically significant in these samples.

When the ABO phenotype frequencies of diabetics are compared with controls matched for sex (Table 7), the differences are seen predominantly in the males where the A1/O relative incidence is 1.4 ($\chi^2 = 3.18$, df = 1, $0.1 > P > 0.05$). The relative incidence in females is 1.9 ($\chi^2 = 0.22$, df = 1). The differences in phenotype frequencies between male and female diabetics and male and female controls are not significant.

The relationship of Rhesus (D) frequencies to age in the control group is more striking (Table 8). There is a significant upward trend of Rhesus negative frequency with increasing age of the subgroup ($P = 0.0096$, test for significance of trend in proportions, Cox, 1970). The trend is present in both sexes, but does not reach statistical significance in either sex taken alone. No trend is found in insulin-taking or in non-insulin-taking diabetics. When age matched controls are compared with insulin-taking and non-insulin-taking diabetics, there are no significant differences in Rhesus phenotype frequencies. When the full Rhesus phenotypes of the control group are analysed with respect to the age of the subjects (Table 9), the only clear trend is that of an increase in the frequency of the cde phenotype with increasing age.

The Rhesus phenotypes show no significant differences between the sexes, neither are any differences apparent when diabetics and sex matched controls are compared.
Discussion

COMPARABILITY OF DISEASED AND CONTROL GROUPS

The diabetic and control populations which form the subject of this report are entirely comparable in terms of their places of birth. The static nature of the population of the Durham area, with about three-quarters of both groups born within the county, is remarkable, and is one of the advantages of this population for studies such as this. Comparability of diseased and control groups with regard to place of birth is not usually shown in studies of this nature and may be important in certain instances, especially when use is made of blood donors as controls.

There have been criticisms of the use of such controls in comparisons of this type. Buckwalter and Knowler (1958) suggested that blood donors are more likely to be of blood group O than a truly random sample of the population, though the situation in countries like the United States, with the presence of professional donors, differs from that in this country. The non-blood donor population gathered in this investigation compares well with ABO results previously published for donors from the same locality.

The ABO System

The finding of a higher frequency of group A₁ (and, therefore, A₁ + A₂) among diabetics than among controls (Table 3) supports the observations of many other workers (Craig and Wang, 1955; McConnell et al., 1956; Bibawi and Khatwa, 1961; Cornil and Pirart, 1961; Doll et al., 1961; Sauer et al., 1963; Révai and König, 1968; Ksenofontor, 1974). Other groups, however, have failed to confirm this (Simpson et al., 1962; Macafee, 1964; Berg et al., 1967) while others have found associations with other groups of this system (Speiser, 1958; Anderson and Lauritzen, 1960; Henry and Poon-King, 1961; Buckwalter, 1964). In the present study, the difference is confined to non-insulin-taking diabetics, and the pooled diabetic patients show an excess of group A₁ only when compared with a very large control group (the blood donors). When current age is taken into account (Table 6), the excess of group A₁ is confined to the older diabetics compared with the older controls, though whether older diabetics show this difference because they are predominantly non-insulin-taking, or non-insulin-taking diabetics differ from controls because they are, by and large, older than insulin-taking diabetics cannot be satisfactorily resolved by this relatively small sample. For reasons to be discussed, the second alternative is favoured.

The results of Table 6 suggest, but do not conclusively show, that the blood group differences in the older subjects are the result of a deficiency of group A₁ subjects among the controls, rather than an excess of A₁ subjects among the patients.

The finding of an apparent excess of group A₁ (and, therefore, of A₁ + A₂) subjects, particularly among male diabetics (Table 7), has been noted before (McConnell et al., 1956; Bibawi and Khatwa, 1961; Révai and König, 1968). This curious finding has never been satisfactorily explained.

The usual interpretation of these phenotype differences is that group A₁ (or A₁) subjects are at a greater risk of developing diabetes, and that this is especially so in males and in persons who develop the disease in later life. There is an alternative explanation, however, which is consistent with the present results and those of some other investigations concerned with the effect of age upon ABO phenotype frequencies in the general population, and which accounts for the sex effect seen and the conflict in published reports in a more satisfactory manner than before.

Jørgensen and Schwarz (1968), in their study of healthy subjects, showed an excess of group O in the elderly compared with a group of younger donors from the same locality. Similarly, Van Houte and Kesteloot (1972), in a study of a large number of male soldiers aged 16 to 60, showed a significantly higher frequency of group O and a significantly lower frequency of group A₁ in the 55 to 60 age group compared with younger age groups. Both groups of workers suggested that group O subjects were at a selective advantage compared with those of group A₁. Jørgensen and Schwarz (1968) considered that relative susceptibility to neoplasm might be responsible. Van Houte and Kesteloot showed significantly higher serum cholesterol levels in persons of group A₁ compared with those of group O, but considered that differential mortality from cardiovascular disease was insufficient alone to account for the effect they found, and differential susceptibility to infections might also play a part.

The results of this study (Table 6) tend to support the observations that older groups of normal people show an increased frequency of blood group O compared with the younger groups. If differential mortality with respect to ABO phenotype does exist and is absent from the diabetic group, an apparent excess of group A₁ subjects among the diabetics would result. Diabetics are envisaged as being independent of this effect, not because they do not die from the disease or diseases responsible, but because their diabetic state is such an overwhelming risk factor that the small differences in mortality, resulting from ABO phenotypes in controls, are not seen.
The greater A/O relative incidence seen in male diabetics would result if differential mortality was more marked among male non-diabetics than among female non-diabetics because of a greater prevalence of, or higher mortality from, the disease(s) in question among males.

The conflict seen in previous reports on this subject may, very largely, be the result of different admixtures of cases among the diseased groups (with regard to treatment category, age at diagnosis, and current age), and different interrelationships of diseased and control groups with respect to age. In general, published reports give insufficient information, especially with regard to the age structure of control groups, to allow this to be evaluated.

Clearly, the hypothesis put forward here is tentative and unsubstantiated. Other investigations, concerned purely with blood donors, have failed to find any relationship between ABO phenotype and age (Roberts, 1948; Bennett and Walker, 1956; Buckwaltz and Knowler, 1958). Our knowledge of the relative survival value of the ABO blood groups is very much in its infancy, though Kesteloot et al. (1977) have strongly advocated matching diseased and control groups for age when studying this polymorphism. It was for this reason that we matched our controls with the cases in respect of age.

Our suggestion has the advantage, however, that, whereas no remotely tenable hypothesis has been advanced for the increased susceptibility to diabetes of group A subjects, there are at least some suggestions for mechanisms connecting ABO status and susceptibility to the development of atherosclerosis (see Morton, 1976, for review). In addition, the proposition that one biological mechanism is responsible for several effects is intrinsically more satisfying than the proposal that each of these several effects is the result of an independent cause, especially if the simpler solution is capable of resolving a conflict in the published data. The testing of this hypothesis, preferably on a prospective basis, in diabetics and controls would be worthwhile.

THE RHESUS SYSTEM

Seeff et al. (1975) have suggested that blood donors especially females, have a higher frequency of Rhesus negative people than the general population. The results presented here (Table 4) do indeed show a higher frequency of this phenotype in donors than in non-donor controls, though the difference is not significant with this small sample.

Analysis of the Rhesus system in this population suggests stronger indications for age matching than are found in an analysis of the ABO system. In the control population, there is a marked age trend (Table 8). This trend cannot be explained by heterogeneity of the sub-groups with regard to sex or place of birth. In the absence of any alternative explanation, we put forward the suggestion that Rhesus negative people are at a selective advantage compared with Rhesus positive people. There is, to our knowledge, no substantiated disease association between the Rhesus system and a common condition capable of explaining these findings. Further work, such as the analysis by age of existing donor records, is clearly required before this suggestion can be accepted. The absence of this trend from the diabetic group may indicate that this is a chance finding, though it may be the result of the fact that the selection is not operational in diabetics in a similar manner to the situation proposed for the ABO system.

Previous studies of the Rhesus phenotype frequencies of diabetics and controls have been conflicting. Buckwaltz and Tweed (1962) found no significant differences between their diseased group and their control group. Berg et al. (1967) found a significant excess of the CDE (R2) haplotype among their diabetics while Scholz et al. (1975) found that the CDe (R3) and cde (r) haplotypes were increased in frequency among diabetics, though the differences were not significant. None of the series which reported results for the D locus only (Craig and Wang, 1955; McConnell et al., 1956; Zeytinoglu 1956; Anderson and Lauritzen, 1960; Simpson et al. 1962) found significant differences between diseased and non-diseased groups.

It is suggested that those series which showed large differences between diabetics and controls for this system are comparing populations that are considerably different in their ages.

There is so little known of the effects of age on ABO and Rhesus phenotypes in the population that it seems hazardous to ascribe relative risks for diabetes to individual phenotypes without stringent matching for age between the diabetic and non-diabetic populations used for comparison.

We gratefully acknowledge the permission of consultant physicians at Dryburn Hospital, Durham, especially Dr R. Mowbray, for permission to study the diabetic patients in their care, and the orthopaedic consultants of the same hospital for access to control subjects, and to the subjects themselves for their co-operation.

Antisera for blood grouping were kindly donated by the Newcastle Blood Transfusion Service, by Dr D. Tills of the British Museum of Natural History, and by the Blood Group Reference Laboratory (Gatliffe Road).

The technical expertise of Mr M. A. Carr and Miss Lesley Bailey is greatly appreciated.
Genetic polymorphisms in diabetics and non-diabetics

DRRW was in receipt of an Addison Wheeler Research Fellowship of the University of Durham during the execution of this work. Financial assistance was received from the Catherine and Lady Grace James Foundation.

References


Requests for reprints to Dr D. R. R. Williams, Dunn Clinical Nutrition Centre, Addenbrookes Hospital, Trumpington Street, Cambridge CB2 1QE.